Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.0046 USD
Change Today 0.00 / 0.00%
Volume 0.0
LGNDZ On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
OTC US
OTC US
As of 8:10 PM 03/31/15 All times are local (Market data is delayed by at least 15 minutes).

ligand pharmaceuticals-cvr (LGNDZ) Snapshot

Open
$0.0046
Previous Close
$0.0046
Day High
$0.0046
Day Low
$0.0046
52 Week High
05/1/14 - $0.02
52 Week Low
11/20/14 - $0.0036
Market Cap
--
Average Volume 10 Days
2.6K
EPS TTM
--
Shares Outstanding
0.0
EX-Date
07/2/10
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for LIGAND PHARMACEUTICALS-CVR (LGNDZ)

ligand pharmaceuticals-cvr (LGNDZ) Related Businessweek News

View More BusinessWeek News

ligand pharmaceuticals-cvr (LGNDZ) Details

Ligand Pharmaceuticals Incorporated operates as a biotechnology company in the United States. The company’s commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis that is used for the treatment of multiple myeloma; bazedoxifene, which is used for the treatment of postmenopausal osteoporosis; and Captisol-enabled Noxafil-IV, a formulation of posaconazole for intravenous (IV) use. Its late-stage development programs include Captisol-enabled Melphalan IV, MK-8931 Beta-Secretase Inhibitor, Captisol-enabled SAGE-547, Sparsentan, Captisol-enabled Delafloxacin-IV, Captisol-enabled Carbamazepine-IV, IRAK4 Inhibitor Program, LTP Technology with Omega-3 Fatty Acids, Biologic Therapeutics Platform, Captisol-enabled Topiramate IV, Lasofoxifene, and Captisol-enabled Lamotrigine IV. The company’s internal product development programs include Glucagon Receptor Antagonist Program, Oral Human Granulocyte Colony Stimulating Factor Program, LTP Platform, Kinase Inhibitors, HepDirect HCV Inhibitor Program, and other programs. Its therapies in development portfolio addresses the unmet medical needs of patients for a range of diseases, including hepatitis, multiple myeloma, muscle wasting, Alzheimer’s disease, dyslipidemia, diabetes, anemia, epilepsy, focal segmental glomerulosclerosis, and osteoporosis. Ligand Pharmaceuticals Incorporated has alliances with GlaxoSmithKline, Amgen, Inc., Merck, Pfizer, Baxter International, and Eli Lilly and Co. The company was founded in 1987 and is headquartered in La Jolla, California.

19 Employees
Last Reported Date: 02/23/15
Founded in 1987

ligand pharmaceuticals-cvr (LGNDZ) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: $510.2K
President and Chief Operating Officer
Total Annual Compensation: $375.4K
Chief Financial Officer and Vice President of...
Total Annual Compensation: $300.5K
Vice President, General Counsel and Secretary
Total Annual Compensation: $288.9K
Compensation as of Fiscal Year 2014.

ligand pharmaceuticals-cvr (LGNDZ) Key Developments

Ligand Pharmaceuticals Incorporated Presents at 2015 Deutsche Bank Pharma OneonOne Day, Mar-26-2015

Ligand Pharmaceuticals Incorporated Presents at 2015 Deutsche Bank Pharma OneonOne Day, Mar-26-2015 . Venue: JW Marriott Denver at Cherry Creek, 150 Clayton Lane, Denver, CO 80206, United States.

Ligand Pharmaceuticals Incorporated Presents at 27th Annual ROTH Conference, Mar-09-2015 02:30 PM

Ligand Pharmaceuticals Incorporated Presents at 27th Annual ROTH Conference, Mar-09-2015 02:30 PM. Venue: The Ritz Carlton, 1 Ritz Carlton Dr, Dana Point, CA 92629, United States. Speakers: John L. Higgins, Chief Executive Officer and Executive Director.

Ligand Pharmaceuticals Incorporated Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014; Provides Earnings Guidance for the First Quarter and Full Year of 2015

Ligand Pharmaceuticals Incorporated reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. Total revenues for the fourth quarter of 2014 were $23.0 million, an increase of 56% compared with $14.7 million for the same period in 2013. Net income was $7.1 million, or $0.34 per diluted share, compared with net income for the fourth quarter of 2013 of $1.9 million, or $0.09 per diluted share. Non-GAAP net income from continuing operations for the fourth quarter of 2014 was $12.5 million, or $0.60 per diluted share, compared with non-GAAP net income from continuing operations for the fourth quarter of 2013 of $7.5 million, or $0.35 per diluted share. Total revenues for 2014 increased 32% to $64.5 million compared with $49.0 million for 2013. Net income from continuing operations for 2014 was $12.0 million, or $0.56 per diluted share, compared with net income from continuing operations of $8.8 million, or $0.43 per share, for 2013. Non-GAAP net income from continuing operations for 2014 was $32.6 million, or $1.52 per diluted share, compared with $19.0 million, or $0.92 per diluted share, for 2013. Net income was $12.02 million, or $0.56 per diluted share, compared with net income of $11.42 million, or $0.43 per diluted share. For the first quarter of 2015, the company expects total revenues to be between $13.0 million and $13.5 million and non-GAAP earnings per diluted share to be between $0.25 and $0.27. The non-GAAP earnings per diluted share guidance does not include changes in contingent liabilities, mark-to-market adjustment for amounts owed to licensors, non-cash stock based compensation expense and non-cash debt related costs. Affirming its previous full-year 2015 financial forecast, the company expects total revenues to be between $81.0 million and $83.0 million, and non-GAAP earnings per diluted share to be between $2.14 and $2.18. The company expects that approximately half of 2015 revenue will be derived from royalties.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LGNDZ:US $0.00 USD 0.00

LGNDZ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for LGNDZ.
View Industry Companies
 

Industry Analysis

LGNDZ

Industry Average

Valuation LGNDZ Industry Range
Price/Earnings 100.0x
Price/Sales 23.5x
Price/Book 56.7x
Price/Cash Flow 124.5x
TEV/Sales 17.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LIGAND PHARMACEUTICALS-CVR, please visit www.ligand.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.